These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30007161)

  • 1. No association of salivary total tau concentration with Alzheimer's disease.
    Ashton NJ; Ide M; Schöll M; Blennow K; Lovestone S; Hye A; Zetterberg H
    Neurobiol Aging; 2018 Oct; 70():125-127. PubMed ID: 30007161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
    Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
    Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic Biomarkers of Alzheimer's Disease as Identified in Saliva using 1H NMR-Based Metabolomics.
    Yilmaz A; Geddes T; Han B; Bahado-Singh RO; Wilson GD; Imam K; Maddens M; Graham SF
    J Alzheimers Dis; 2017; 58(2):355-359. PubMed ID: 28453477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?
    Andriuta D; Moullart V; Schraen S; Devendeville A; Meyer ME; Godefroy O;
    J Alzheimers Dis; 2016; 51(3):793-800. PubMed ID: 26923012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.
    Haris M; Yadav SK; Rizwan A; Singh A; Cai K; Kaura D; Wang E; Davatzikos C; Trojanowski JQ; Melhem ER; Marincola FM; Borthakur A
    Neuroimage Clin; 2015; 7():598-604. PubMed ID: 25844314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
    J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tau positron emission tomography using [
    Kang JM; Lee SY; Seo S; Jeong HJ; Woo SH; Lee H; Lee YB; Yeon BK; Shin DH; Park KH; Kang H; Okamura N; Furumoto S; Yanai K; Villemagne VL; Seong JK; Na DL; Ido T; Cho J; Lee KM; Noh Y
    Neurobiol Aging; 2017 Nov; 59():210-219. PubMed ID: 28890300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tau PET in Alzheimer disease and mild cognitive impairment.
    Cho H; Choi JY; Hwang MS; Lee JH; Kim YJ; Lee HM; Lyoo CH; Ryu YH; Lee MS
    Neurology; 2016 Jul; 87(4):375-83. PubMed ID: 27358341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimation of Tau and Phosphorylated Tau181 in Serum of Alzheimer's Disease and Mild Cognitive Impairment Patients.
    Shekhar S; Kumar R; Rai N; Kumar V; Singh K; Upadhyay AD; Tripathi M; Dwivedi S; Dey AB; Dey S
    PLoS One; 2016; 11(7):e0159099. PubMed ID: 27459603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimer's Disease.
    Deters KD; Risacher SL; Kim S; Nho K; West JD; Blennow K; Zetterberg H; Shaw LM; Trojanowski JQ; Weiner MW; Saykin AJ;
    J Alzheimers Dis; 2017; 58(4):1245-1254. PubMed ID: 28550246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer's disease patients: A CSF and FDG PET study.
    Chiaravalloti A; Barbagallo G; Ricci M; Martorana A; Ursini F; Sannino P; Karalis G; Schillaci O
    Brain Res; 2018 Jan; 1678():116-122. PubMed ID: 29066367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic interaction between amyloid and tau predicts the progression to dementia.
    Pascoal TA; Mathotaarachchi S; Shin M; Benedet AL; Mohades S; Wang S; Beaudry T; Kang MS; Soucy JP; Labbe A; Gauthier S; Rosa-Neto P;
    Alzheimers Dement; 2017 Jun; 13(6):644-653. PubMed ID: 28024995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Florbetapir positron emission tomography and cerebrospinal fluid biomarkers.
    Hake A; Trzepacz PT; Wang S; Yu P; Case M; Hochstetler H; Witte MM; Degenhardt EK; Dean RA;
    Alzheimers Dement; 2015 Aug; 11(8):986-93. PubMed ID: 25916563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.
    Mazzeo S; Santangelo R; Bernasconi MP; Cecchetti G; Fiorino A; Pinto P; Passerini G; Falautano M; Comi G; Magnani G
    J Alzheimers Dis; 2016 Oct; 54(4):1495-1508. PubMed ID: 27589522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE).
    Jessen F; Spottke A; Boecker H; Brosseron F; Buerger K; Catak C; Fliessbach K; Franke C; Fuentes M; Heneka MT; Janowitz D; Kilimann I; Laske C; Menne F; Nestor P; Peters O; Priller J; Pross V; Ramirez A; Schneider A; Speck O; Spruth EJ; Teipel S; Vukovich R; Westerteicher C; Wiltfang J; Wolfsgruber S; Wagner M; Düzel E
    Alzheimers Res Ther; 2018 Feb; 10(1):15. PubMed ID: 29415768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical Comparison of Different Biomarkers for Alzheimer's Disease in a Clinical Setting.
    Weise D; Tiepolt S; Awissus C; Hoffmann KT; Lobsien D; Kaiser T; Barthel H; Sabri O; Gertz HJ
    J Alzheimers Dis; 2015; 48(2):425-32. PubMed ID: 26402006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased cerebrospinal fluid levels of double-stranded RNA-dependant protein kinase in Alzheimer's disease.
    Mouton-Liger F; Paquet C; Dumurgier J; Lapalus P; Gray F; Laplanche JL; Hugon J;
    Biol Psychiatry; 2012 May; 71(9):829-35. PubMed ID: 22281122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.